These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21338872)

  • 21. Neurocognitive enhancement: what can we do and what should we do?
    Farah MJ; Illes J; Cook-Deegan R; Gardner H; Kandel E; King P; Parens E; Sahakian B; Wolpe PR
    Nat Rev Neurosci; 2004 May; 5(5):421-5. PubMed ID: 15100724
    [No Abstract]   [Full Text] [Related]  

  • 22. Enhancing cognition in the intellectually intact.
    Whitehouse PJ; Juengst E; Mehlman M; Murray TH
    Hastings Cent Rep; 1997; 27(3):14-22. PubMed ID: 9219019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.
    Sahakian BJ; Morein-Zamir S
    Lancet Psychiatry; 2015 Apr; 2(4):357-62. PubMed ID: 26360089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses.
    Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140
    [No Abstract]   [Full Text] [Related]  

  • 25. [Can intelligence be increased with drugs?].
    Virsu V
    Duodecim; 2000; 116(15):1525-6. PubMed ID: 12001471
    [No Abstract]   [Full Text] [Related]  

  • 26. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
    Strnad J; Bahro M
    Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
    [No Abstract]   [Full Text] [Related]  

  • 28. Closing thoughts for cognitive enhancement.
    Kantak KM; Wettstein JG
    Handb Exp Pharmacol; 2015; 228():451-9. PubMed ID: 25977093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroethical issues in cognitive enhancement.
    Sahakian BJ; Morein-Zamir S
    J Psychopharmacol; 2011 Feb; 25(2):197-204. PubMed ID: 20212064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drug development for cognitive enhancement in mental health: challenges and opportunities.
    Insel T; Krystal J; Ehlers M
    Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacologic treatment for cognitive disorders: an update].
    Lestage P
    Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preface to cognitive enhancement.
    Kantak KM; Wettstein JG
    Handb Exp Pharmacol; 2015; 228():v. PubMed ID: 26317138
    [No Abstract]   [Full Text] [Related]  

  • 33. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia.
    Caston JC; Diehl LA; Hedgepath AW
    J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232
    [No Abstract]   [Full Text] [Related]  

  • 34. AMPA receptor potentiators as cognitive enhancers.
    O'Neill MJ; Dix S
    IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people.
    Boot BP; Partridge B; Hall W
    Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles].
    Metzinger TK
    Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new treatment for hypoxic brain injury?
    Flood P
    Anesth Analg; 2007 Sep; 105(3):559-60. PubMed ID: 17717206
    [No Abstract]   [Full Text] [Related]  

  • 39. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
    Karasawa J; Hashimoto K; Chaki S
    Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.